PSTX News and Press, Poseida Therapeutics Inc. From 06/29/22

Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products PR Newswire Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing ...

Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 2, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering...

Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting PR Newswire Preclinical data supports potential of P-ckit-ALLO1 as a less toxic preconditioning agent for hematopoietic stem cell (HSC) transplants ...

Poseida Therapeutics press release (NASDAQ:PSTX): Q1 GAAP EPS of -$0.93 misses by $0.26. Revenue of $1.44M beats by $0.61M. As of March 31, 2022, the Company's cash and cash equivalents balance was $183.5 million. For further details see: Poseida Therapeutics GAAP EPS of -$0.93 mis...

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene...

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting PR Newswire Preclinical data to be presented supports potential of anti-c-kit CAR-T cells as a highly specific and less toxic conditioning regimen for hematopoietic stem ce...

Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference PR Newswire SAN DIEGO , April 28, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engine...

Poseida Therapeutics press release (NASDAQ:PSTX): Q4 GAAP EPS of $0.02. Revenue of $31.2M. As of December 31, 2021, cash and cash equivalents balance was $206.3 million, which does not include net proceeds of $28.3 million from the restructuring of the Company's debt arrangement, pursuant to ...

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 Company announced first strategic collaboration with Takeda focused on deploying its platform technologies to develop non-viral in vivo gene therapies Company received a saf...

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , March 1, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineer...